Form 4: Dexcom Executive Sadie Stern Reports Stock Transactions Following Vesting of Performance Stock Units
SEC Form 4 Filing
Dexcom's EVP, Chief HR Officer, Sadie Stern, sold 2,093 shares to cover tax obligations after 5,586 performance stock units vested.
Summary
- Sadie Stern, EVP and Chief HR Officer at Dexcom, acquired 5,586 shares of common stock on January 28, 2025, due to the vesting of performance stock units (PSUs) granted on March 8, 2022.
- Following the vesting, Ms. Stern sold 2,093 shares on January 29, 2025, at a price of $86.9141 per share to cover tax withholding obligations.
- The sale was not a discretionary trade but a mandatory 'sell to cover' transaction as per Dexcom's equity incentive plans.
- After these transactions, Ms. Stern beneficially owns 74,261 shares of Dexcom common stock.
- This total includes 43,283 unvested restricted stock units (RSUs) that will vest through March 8, 2027.
Sentiment
Score: 7
Explanation: The document reflects standard executive compensation practices and does not indicate any significant positive or negative news. The transactions are routine and expected.
Industry Context
This is a routine filing related to executive compensation and is common for publicly traded companies. It reflects the vesting schedule of equity grants and the subsequent sale of shares to cover tax liabilities.
Comparison to Industry Standards
- The vesting and 'sell to cover' mechanism is a standard practice in the tech and biotech industries, where equity compensation is a significant part of executive pay.
- Companies like Medtronic, Abbott, and Boston Scientific also use similar equity compensation plans for their executives.
- The vesting schedules and tax withholding practices are generally consistent with industry norms.
Stakeholder Impact
- The transactions have a minimal impact on shareholders as they are routine and related to executive compensation.
- The sale of shares to cover tax obligations is a standard practice and does not indicate any change in the company's fundamentals.
Key Dates
| Date | Description |
|---|---|
| 03/08/2022 | Performance stock units granted to Sadie Stern that vested on January 28, 2025. |
| 03/08/2022 | Restricted stock units granted to Sadie Stern that will vest through March 8, 2025. |
| 03/08/2023 | Restricted stock units granted to Sadie Stern that will vest through March 8, 2026. |
| 03/08/2024 | Restricted stock units granted to Sadie Stern that will vest through March 8, 2027. |
| 01/28/2025 | Performance stock units vested, resulting in the acquisition of 5,586 shares. |
| 01/29/2025 | 2,093 shares sold to cover tax obligations at $86.9141 per share. |
| 01/30/2025 | Form 4 filing date. |
Keywords
Dexcom, stock transaction, performance stock units, restricted stock units, insider trading, executive compensation, equity incentive plans, tax withholding, Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.